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Brain metastases in non-small cell lung cancer (NSCLC) patients are more often
detected due to imaging modalities improvements but also emerge because of improved
treatments of the primary tumor which lead to a longer survival. In this context,
development of leptomeningeal metastases (LM) is a devastating complication and its
prognosis remains poor despite advances in systemic and local approaches. Histology
characterization of NSCLC and molecular expression influence LM management. For
those with “oncogene addiction,” new generation epidermal growth factor receptor
(EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) were
developed to strongly penetrate the blood-brain barrier (BBB) with the aim to prevent
central nervous system cancer dissemination, eventually impacting on LM appearance
and its subsequent management. Systemic chemotherapy, often combined with
intrathecal chemotherapy (when possible), was one of common indications for lung
cancer patients affected by LM, without driver mutations and a good performance status
but currently, with the advent of innovative systemic approaches treatment solutions in
this subgroup of patients are rapidly evolving. Whole brain radiation therapy (WBRT) is
the conventional treatment for patients with brain metastases. Furthermore, modern
radiation techniques, as stereotactic radiotherapy (SRT), improve outcomes in those
cases with a limited number of lesions. However, LM represent a minority of CNS
metastases and few literature data are available to drive the radiotherapy approach.
Considering all relevant progress made in this setting, after a literature review, the aim
of this paper is to discuss about recent developments and therapeutic options in LM
management of non-oncogene addicted NSCLC.
Keywords: non-small cell lung cancer (NSCLC), brain metastases, leptomeningeal metastases, chemotherapy,
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INTRODUCTION
Non-small cell lung cancer (NSCLC) is characterized by a high incidence of central nervous system
(CNS) dissemination, with approximately 40% of patients developing brain metastases (BM) in
the course of their disease (1, 2) and leptomeningeal metastases (LM) appearance in a smaller
percentage (3–5%) (3). Particularly, LM incidence among NSCLC patients is 3.8% more frequent
in adenocarcinoma subtype, with about a third of those patients having concomitant BM (4). LM
usually manifest as a late complication, which have been reported to emerge as late as up to 112
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months after initial diagnosis (5). LM cases are increasing
in incidence as a result of improved survival in subgroups
of patients with targetable mutations treated with molecular
therapies, but also because of modern neuro-imaging tools, able
to clearly identify even small foci of meningeal dissemination
(6–8). Median survival of NSCLC patients affected by LM
is particularly poor even with signs of improvement, from a
historical median survival of 1–3 to 3–11 months with novel
therapies and integration of local and systemic treatments (9).
Specific treatments of LM depends on histology characterization
of NSCLC, molecular expression, time of appearance and
patient’s performance status. Molecularly targeted therapies
and immunotherapy showed antitumor activity for brain
metastases although effectiveness in cytologically confirmed and
symptomatic LM is still limited or unknown (3). Systemic and
intrathecal (IT) chemotherapy with site-specific radiotherapy
are usually applied, particularly in non-oncogene addicted
NSCLC, while up to one-third of the patients are treated with
best supportive care alone. Despite the lack of the standard
treatments, active treatments have been associated independently
with longer overall survival (OS) (10). Recent advances in the
understanding of LM biology in NSCLC patients along with the
development of highly active targeted drugs for tumors with
specific genetic alterations, helped to redefine the prognosis in
this subgroup of patients and the same evolution is largely
awaited in those NSCLC patients without oncogene addiction
(5, 11–14). Based on literature review, this paper aims to discuss
about recent developments and therapeutic options of LM in
NSCLC patients without driver mutations.
BIOLOGY OF BLOOD BRAIN BARRIER
AND DRUG DELIVERY
The blood–brain barrier (BBB) is constituted by a continuous
stratum of endothelial cells connected by tight junctions
surrounded by pericytes and perivascular end feet of astrocytes,
thus being a highly selective barrier which separates systemic
circulation from cerebrospinal fluid (CSF) (15).
BBB maintains CNS homeostasis by enabling the transport
of selected substances only, through a combined result of influx
and efflux mechanisms. Therapeutic efficacy in this area is
determined by whether drug concentrations can be achieved in
the CSF and these differ as a result of multiple conditions. The
ability of a drug to cross the BBB is substantially improved by
particular physic-chemical properties, including low potential
for active efflux, few rotatable bonds, small polar surface
area, few hydrogen bond donors (9). For instance, anticancer
therapeutics (tyrosine kinase inhibitors or chemotherapeutic
agents), are substrates of efflux transport proteins, such as P-
glycoprotein, which is responsible for the transport of most
drugs outside the intracranial region. Most chemotherapy
agents have low CSF concentrations, with relevant liquor
permeability reported only for temozolomide, methotrexate
and topotecan (16–19), however predicted CNS penetration
does not necessary correlate with known response rates to
chemotherapeutic agents. Moreover, free diffusion of molecules
across the BBB requires both lipophilicity and low molecular
weight (less than 0.5 kDa): chemotherapy drugs are usually
larger than 150 kDa, hydrophilic and frequently protein-bound
molecules, therefore unable to penetrate an intact BBB (20–
23). In this context, growing scientific evidence highlights that
CNS metastases cause BBB interruption; this process, probably
due to tumor neo-angiogenesis, lead to generate new vessels
lacking of structural and physiological features of normal
BBB, thus favoring the passage of drugs into the brain (24,
25). The same hypothesis emerges after whole brain radiation
(WBRT) approach, thus providing a biologic rationale for using
concomitant or sequential systemic and local treatments in these
cases (26, 27).
DIAGNOSIS OF LEPTOMENINGEAL
METASTASES
LM involve penetration of inner layers of meninges and
subarachnoid space in which CSF circulates. Its diagnosis
is specifically based on three different assessments: clinical
signs and symptoms, CSF cytological examinations and neuro-
radiological imaging.
Early clinical presentation can be subtle and may include
headaches and back pain, cranial nerve deficits, cauda equine
symptoms or signs, visual disturbances, diplopia, hearing loss and
neurocognitive syndromes. In later stages, symptoms related to
elevated intracranial pressure could occur (28, 29). Cytological
identification of malignant cells in CSF is the gold standard for
diagnosis of LM. The sensitivity of the initial lumbar puncture
was reported to be as low as 50%, with a potential increase to
75–85% with a second CSF analysis (30). A meningeal biopsy
is rarely needed to confirm a clinical suspect. A recent study
performed by Jiang et al. demonstrated that the use of next-
generation sequencing (NGS) performed on cerebrospinal fluid
circulating tumor cells (CSF-CTC) may be a more sensitive and
an effective way to diagnose LM, serving also as a liquid biopsy
for gene profiles in NSCLC patients with LM (31). Besides clinical
and cytological diagnosis, brain and spine imaging are able to
identify involved sites, even in cytology-negative cases (32).
Magnetic resonance imaging (MRI), ideally with a 3 Tesla
scanner is the most useful imaging modality for the detection of
LM. Both T1 with and without contrast enhancement and high
resolution T2 fluid attenuated inversion recovery sequences post-
contrast are important in establishing a radiological diagnosis of
LM.
Particularly the disruption of BBB in presence of CNS
metastases is often evidenced by peritumoral edema and
accumulation of contrast during the imaging scans and, as more
recently observed, penetration of CNS metastases is identified by
nuclear medicine tracers, such as 18-Sodium Fluoride (33).
The EANO-ESMO clinical practice guidelines propose to
classify LM by using two major criteria, being “type I” those LM
when the diagnosis has been verified citologically or histologically
and “type II” in the absence of verification. While on the basis of
the neuroimaging findings: linear leptomeningeal disease (type
A), nodular leptomeningeal disease (type B), both (type C) or
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neither nor, e.g., no neuroimaging evidence of LM except possibly
hydrocephalus (type D) (34).
TREATMENT OPTIONS OF
LEPTOMENINGEAL METASTASES
Treatment of LM is preferentially multidisciplinary and mostly
indicated when diagnosis is unequivocal or symptoms are
strongly suggestive, in case of negative cytology.
The goals of treatment in patients with LM are to improve
or stabilize the neurologic status of the patient, maintain or
regain quality of life and optimally to prolong survival together
with marginal toxicity. Limited data are available to establish
treatment recommendations in the management of LM: no
randomized trials proved a survival benefit of a specific treatment
modality and, accordingly, the optimal strategy is still poorly
defined, particularly in non-oncogene addicted NSCLC. In this
last setting of patients, palliative radiotherapy to symptomatic
sites of disease, cytotoxic chemotherapies, intrathecal therapy (or
a combination of these modalities) are traditionally considered,
with the new innovative immunotherapy chance (35–39).
Radiation Therapy
In the era of improved radiation modalities, local treatment of
BM is rapidly improving: a growing amount of data support an
integrate use of WBRT or stereotactic radiosurgery (SRS) with
systemic treatment in a variety of clinical scenarios, together with
alternative radiation approaches, such as intensity modulated
radiation therapy (IMRT) or even proton beam therapy, when
applicable (40–42).
LM represent a minority of CNS metastases (11–20%) (43, 44)
and less data are available to inform decisions about therapy.
RT is mainly administered for symptoms alleviations, CSF flow
correction or for debulking to facilitate chemotherapy.
WBRT is typically used in cases of concurrent brain
metastases or major meningeal cerebral involvement (45).
For BM dose and fractionation scheme is at the discretion
of the treating radiation oncologist, though most commonly
used dose and fractionation schemes are 20Gy in 5 fractions
of 4Gy (standard schedule in Europe) and 30Gy in 10
fractions of 3Gy (46). For LM focal radiation therapy is
recommended on symptomatic, bulky or obstructive sites and
the dose depends on performance status (20–40Gy in 5–
20 fractions), volume to treat and available techniques (47).
Different studies reported a survival difference in favor of
patients with better performance status after various treatments,
including WBRT (48, 49). Gani et al. evidenced that WBRT
alone in patients with LM from breast and lung cancer is an
effective palliative treatment for patients unfit for chemotherapy
and poor performance status (49). As tumor dissemination
affects the whole CSF compartment, according to some studies,
the complete craniospinal axis should be encountered as target
volume. Favorable results have been reported in small series.
To determine the effects of craniospinal irradiation (CSI) a
retrospective study of 16 patients with LM (mostly from
breast and lung cancer) was conducted by Hermann et al.
In this study, ten patients were additionally treated with
intrathecal methotrexate. The authors conclude that craniospinal
radiotherapy is feasible and effective for palliative treatment of
LM (36).
However, craniospinal irradiation (CSI) is generally
not recommended, as it is assumed to cause substantial
myelotoxicity. In fact, in his review, Chamberlain stated that
“whole neuroaxis radiation of the craniospinal axis is rarely
indicated in the treatment of LM in solid tumors” (50).
Conformal radiotherapy may help to limit bone marrow and
neurotoxicity making focal radiotherapy better tolerated. Proton
therapy is only available in a few centers, but this approach
promises further reduction of toxicity and effectiveness from CSI
(51, 52).
Focal RT administration in fractionated regimens, such as
involved-field or stereotactic RT or administered in single
fractions (radiosurgery), can be used to treat nodular disease and
symptomatic cerebral or spinal sites (34). By contrast, stereotactic
radiosurgery (SRS), which is a radiation therapy technique in
which multiple focused radiation beams intersect over a target,
results in delivery of a highly conformal, high-dose of radiation
to the target and minimal radiation to the surrounding normal
tissues. In patients with BM a Gamma Knife Radiosurgery
(GKRS) is typically used, depending upon the volume and
location prescription doses typically range from 15 to 24Gy for
single fraction session (53). GKRS allow to achieve high rates of
local control, and is able to delay the need for WBRT thus avoid
potential neurocognitive toxicities, although a phase 2 RTOG
study suggested that concomitant administration of memantine
together with WBRT may reduce and delay subsequent cognitive
consequences (54). Few studies have reported on the role of SRS
in the setting of LM (55, 56). In the small and heterogeneous
study by Wolf et al. the prescription tumor margin dose was
a median of 16Gy (11–20Gy) to the 50–80% isodose volumes.
The authors suggested SRS capable to provide high rates of
local control for restricted LM with a median survival of 10
months and with 60% of the population alive at 6 months. SRS
for focal LM is preferable in those patients who are eligible
for systemic therapy, including immuno-therapies and targeted
therapies, which can potentially further prolong overall survival.
Involved field radiotherapy (IFRT) is considered to be the
standard of care for palliative treatment of LM. Relevant to
this, the US National Comprehensive Cancer Network (NCCN)
2017 guidelines for management of LM recommend Intrathecal
Chemotherapy (IT) in combination with IFRT in patients with
good prognosis disease (as defined by high performance status,
non-fixed neurologic deficits, minimal systemic disease, and
reasonable options for systemic disease treatment). Patients not
meeting criteria for good prognosis are recommended to undergo
IFRT to symptomatic sites or best supportive care (45). Up
to now, no randomized clinical trial to assess the efficacy and
tolerance of RT in LM have been conducted, however use of
radiation therapy in NSCLC patients with LM, particularly in
those not presenting driver mutations, needs to be better defined
in clinical trials. Concomitant strategies with ITC are currently
not considered as standard care due to the toxicity profile. Phase
II clinical trial of combination therapy with involved field RT
combined with concurrent intrathecal-MTX or intrathecal-ARA-
C is currently underway (57).
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Table 1 summarize the published studies from 2000: different
types of radiation modality on different histologies in patients
with LM are included (36, 49, 56, 58–61).
In the last few years, understanding of immune system’s role
in the response to ionizing radiation is progressively raising,
novel opportunities to study how to combine immunotherapy
with radiation-induced cell killing are revolutionizing cancer
treatment. Accumulating preclinical and clinical data showed
that combination of radiation techniques with immunotherapy
stimulates immune response, improves locoregional and distant
control finally resulting in better OS. Radiation appears to
stimulate the immune system through multiple mechanisms,
including the increase of the tumor-associated antigens (TAAs)
availability, improving antigen presentation and subsequent
stimulation of effector T cells, and enhancing infiltration of
dentritic cells and T cells into the tumor microenvironment.
The limited evidence for immunotherapy to date in the
treatment of BM and LM stems from the deliberate exclusion
of patients with active brain metastases from many large
randomized trial assessing drug efficacy (61–63). However,
comparable efficacy of immunotherapy agents in the brain
and at extracerebral sites with radiation therapy has been
recently reported by an ongoing study from Goldberg et al.
In this initial analyses 36 cases were considered, 18 with
melanoma and 18 with NSCLC. Patients were treated with
pembrolizumab 10 mg/kg every 2 weeks until progression, no
target lesions were previously resected, 20 patients received
some form of local CNS therapy prior to enrollment (9 and
7 lesions had been treated respectively with WBRT and SRS,
75 lesions were untreated). The primary endpoint was BM
response rate and the initial results presented demonstrated a
systemic benefit from immunotherapy in patients withmetastatic
melanoma and NSCLC (61). Combining immunotherapeutic
agents with stereotactic radiosurgery appears to enhance
both local and distant control, and result in better survival
(42).
Finally, other types of RT in patients without obstruction
to CSF flow, as radioimmunotherapy (RIT) consisting of intra
CSF administration of radioisotopes like iodine-131 (131I)
and yttrium-90 (90Y) with radiolabeled antibodies as HMFG1,
3F8 and 8H9 have been utilized, but further improvement
in the pharmacokinetic modeling of CNS RIT modality
should refine this emerging therapy to fit the clinical context
(63, 64).
Systemic Therapy
In the last decade, the advent of EGFR- tyrosine kinase inhibitors
(TKIs) has improved the prognosis of NSCLC patients harboring
EGFR mutations on both CNS metastases and extracranial
disease, by contrast non-oncogene addicted NSCLC prognosis
remains extremely poor.
The role of chemotherapy for patients with CNS metastases
from NSCLC has been neglected for years, because of prevailing
belief that chemotherapeutic drugs cannot cross at all the
BBB. A Platinum based-combination (preceded or not by
a local radiation treatment) is the mainstay of treatment in
TABLE 1 | Selected trials published of radiation modality treatment with or without chemotherapy/immunotherapy association in patients with LM/BM [BM, brain
metastasis; LM, leptomeningeal metastasis, Involved-field radiotherapy (IF-RT), Intrathecal chemotherapy (IC), Craniospinal Irradiation (CSI) Methotrexate (MTX), Non
available (NA), Not reached (NR), Patients (pt)].
Author and year Number of
patients
Histology CNS
metastasis
Status of EGFR/ALK
NSCLC
Treatment Median overall
survival (mOS)
(weeks)
Wolf et al. (56)
(retrospective)
16 8 NSCLC
5 breast cancer
3 other
LM 4 EGFR mutant
1 ALK-rearranged
3 no mutation
SRS (5 pt had prior
WBRT)
40
Pan et al. (58)
(prospective phase
2 study)
59 32 NSCLC
10 SCLC 11
breast cancer
6 Other
LM NA Concomitant IF-RT +
IC MTX
26
Ozdemir et al. (59)
(retrospective)
51 30 SCC
21 Adenocarcinoma
LM NA WBRT 15, 6
Brower et al. (60)
(retrospective)
124 32 NSCLC
22 breast cancer
21 SCLC
49 other
LM NA Chemotherapy +
WBRT
9, 2
Gani et al. (49)
(retrospective)
27 20 breast cancer
7 lung cancer
LM NA WBRT 8, 1
Hermann et al.
(36) (retrospective)
16 9 breast cancer
5 lung cancer
2 other
LM NA CSI
(10 pt CSI + ITC MTX)
12
8 RT alone
16 RT-ITC
Goldberg et al.
(61) (two-cohort
phase II trial)
36 18 melanoma
18 NSCLC
BM KRAS mutant 4
EGFR mutant 1
ALK-rearranged 1
PD-L1 positive 18
Pembrolizumab
20pt prior CNS therapy
(9 lesions WBRT 7
lesions SRS)
Melanoma (NR) NSCLC
30, 8
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TABLE 2 | Platinum-based chemotherapy trials for CNS from NSCLC (BM, brain metastasis; LM, leptomeningeal metastasis).
Author and year Number of
patients
CNS metastasis Histology Treatment Intracranial RR
(IRR, %)
Median overall survival
(mOS) (weeks)
Robinet et al. (71) 171 BM NSCLC Cisplatin-Vinorelbine 33 24
Franciosi et al. (68) 43 BM + LM NSCLC Cisplatin-Etoposide 37 32
Barlesi et al. (72) 43 BM NSCLC Cisplatin-Pemetrexed 41.9 29.6
Cotto et al. (69) 31 BM NSCLC Cisplatin-Fotemustine 23 16
Fujita et al. (67) 30 BM NSCLC Cisplatin-Ifosfamide-Irinotecan 50 56
Bailon et al. (73) 26 BM NSCLC Carboplatin-Pemetrexed 40 39
Cortes et al. (65) 26 BM NSCLC Paclitaxel Cisplatin/Vinorelbine-
Gemcitabine
38 21.4
Minotti et al. (66) 23 BM NSCLC Cisplatin-Teniposide 35 21
Bernardo et al. (70) 22 BM NSCLC Carboplatin-Vinorelbine-
Gemcitabine
45 33
advanced non-small cell lung cancer (aNSCLC) with BM and
or LM NSCLC at diagnosis without oncogenic driver mutations
or programmed death-ligand 1 (PD-L1) tumor proportion
score (TPS) values ≥ 50% (65–73). Table 2 summarize
platinum-based chemotherapy for NSCLC patients with CNS
(65–73).
Pemetrexed is a compound currently approved both in
combination with platinum in first-line setting and as a
single agent in maintenance or second line setting for the
treatment of non-squamous cell carcinoma (74–77). Although
a penetration of CNS of less 5%, pemetrexed demonstrated a
consistent activity against BM from NSCLC with an intracranial
RR of 30.8−41.9% and an overall clinical benefit of 63%
without specific data for LM (72, 73, 78, 79) Bevacizumab
is an anti-VEGF monoclonal antibody approved in patients
affected by locally advanced or metastatic non-squamous cell
carcinoma (80). Recent reports showed that bevacizumab
improve intra-tumor penetration of other chemotherapeutic
agents, such as carboplatin or paclitaxel by normalizing
angiogenesis at the tumor site with a low incidence of CNS
hemorrhage (81, 82). Additionally, bevacizumab appeared to
alter neuroimaging characteristics of LM, confounded diagnosis
and possibly also influenced the pattern of tumor spread of
LM (83). Bevacizumab is also known as a “steroid-sparing”
drug, that allows reduction in steroid dosage and achieves
reductions in mass effect and peritumoral edema getting better
control of neurological symptoms (84). In those patients with
squamous histology and low PD-L1 expression, gemcitabine
and taxanes are largely prescribed, also in patient with
BM, but no specific data about LM are available (70, 85,
86).
For both squamous and non-squamous cell carcinoma
without oncogene-addiction and TPS ≥ 50%, pembrolizumab
represents the standard of care in the first-line setting.
Data on the efficacy of immunotherapy for BM or LM are
currently limited, because of the exclusion of these patients
from clinical trials (38, 87–89). In the trial by Goldberg
et al., already mentioned above, 36 patients with BM were
treated with pembrolizumab. Among patients with NSCLC, BM
response rate was 33% and treatment-related serious adverse
events were rare. Several aspects of study population need
to be considered looking at the results: patients eligible for
this trial were those with BM < 20mm, asymptomatic and
not requiring corticosteroids to control neurologic symptoms,
without autoimmune disease and with no prior treatment
with agents targeting PD-1/PD-L1 (61). Only preliminary data
are available on efficacy of anti-programmed cell death 1
(PD-1) agents (nivolumab, pembrolizumab) or anti-PD ligand
1 (atezolizumab) in NSCLC patients with BM. A review on
efficacy and safety of nivolumab conducted by Dudnik in
five patients with aNSCLC with new/progressing asymptomatic
CNS metastasis (including patient with LM) suggested that
immune-check inhibitors might have an intracranial activity.
Two intracranial responses were observed, while stabilization of
LM was achieved in 10 weeks (90). In the Italian Nivolumab
Squamous NSCLC Expanded Access Program, 38 patients
with treated and asymptomatic BM were included, none of
them with LM. In this subgroup of patients immunotherapic
agent obtained a disease control rate equal to 47.3% (91).
On the other hand, Otsubo et al., reported a case report of
the development of LM during a pronounced response of
the primary tumor to pembrolizumab therapy in a NSCLC
patient (92). Relevant to this, in the era of molecular oncology
it will be important to consider genomic differences in
systemic malignancies that can implicate a distinct immune
response.
Looking at other type of compounds, a phase II trial with
abemaciclib (orally bioavailable inhibitor of cyclin-dependent
kinases 4 and 6) (93) is ongoing in patients with LM fromNSCLC
and solid tumors (94).
Intra-Thecal Chemotherapy
Intrathecal administration is the most common method to
deliver chemotherapeutic agents in non-nodular and non-
bulky LM in solid tumors, although efficacy compared to
systemic administration and choice of regimen are poorly
understood due to limited randomized controlled trials
(95). Systemic chemotherapy, which may be combined
with intrathecal chemotherapy, remains standard treatment
for lung cancer patients with LM and a good-risk profile
(45).
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Several retrospective studies demonstrated a survival benefit
from IT-therapy. Because of the paucity of available patients,
LM studies often accrue multiple primary histologies. Most
reports of intrathecal LM treatments include patients who
simultaneously receive systemic agents (29, 95–98). Although
the compounds routinely used for intra-CSF treatment do not
have a key role as single agents for systemic treatment of
most common cancers causing LM, three agents are commonly
prescribed for the intrathecal treatment of LM: methotrexate
(98), cytarabine (including liposomal cytarabine) (99, 100) or
thioTEPA (8). Several schedules have been proposed, without
agreement on optimal dose, frequency of administration or
optimal duration of treatment. No intra-CSF agent has shown
a significant survival advantage over another (8, 99, 100). Up to
now most of the patients are treated until progression or for 1
year, if tolerated. In the absence of evidence from appropriate
clinical trials, clinical symptoms,MRI and CSF findings, as well as
tolerance of treatment, guide individual decisions on the duration
of treatment (34). Pemetrexed is a newer generation multi-
targeted anti-folate agent and, compared with methotrexate,
has better tolerability, exhibits a more favorable side effect
profile, and possesses fewer-drug interactions (78). A phase I
trial (NCT03101579) is ongoing to define safety profile and
clinical response rate associated with this specific intrathecal
therapy (101).
CONCLUSION
LM is undoubtfully a serious complication in NSCLC patients.
Prognosis remains poor, even with the use of personalized
treatments, principally due to low penetration into the CSF
of currently used agents. To our knowledge no randomized
trial has demonstrated a clear survival benefit of any single
modality in the treatment of LM. The optimal treatment
strategy involves a multi- disciplinary approach. The increasing
prevalence of LM warrants further investigation into therapies
and prognostic variables to serve as a guide for treatment
recommendations and patients counseling. An improved
understanding of the biologic mechanisms underlying tumor
CNS metastases and novel available diagnostic tools will
allow for patient-tailored treatment strategies. Future well-
designed randomized controlled studies are needed to evaluate
the efficacy of chemotherapeutics, immunotherapies and
radiation treatment in this specific subgroup of patients
and, more specifically, in those without an “oncogene
addiction.”
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